- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02501356
Effects of ISOThrive on Bodyweight, Body Composition, Hunger/Satiety and Cardiac Risk Measures in Overweight Adults (ISOThrive)
March 25, 2020 updated by: Griffin Hospital
To compare the effects of daily intake of the ISOThrive supplement vs. a placebo on the primary outcome measure of body weight and secondary outcome measures (hunger/satiety, health-related measures and self-reported quality of life) in a group of overweight but otherwise healthy adults.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Hypothesis
The investigator's hypothesize that daily intake for a 3-month period of the ISOThrive supplement vs. a placebo will demonstrate beneficial effects on the primary outcome measure of body weight and secondary outcome measures (hunger/satiety, health-related measures and self-reported quality of life) in a group of overweight adults.
Specific Aims
- To determine the effects of the ISOThrive supplement on body weight in overweight adults encouraged to reduce calories and exercise regularly, but on an unrestricted diet and without specific exercise instruction. Specifically, to demonstrate a clinically meaningful reduction in body weight in a group of overweight adults after 3 months of daily consumption of the ISOThrive supplement.
- To determine the effects of the ISOThrive supplement on hunger/satiety, body composition, waist circumference, blood pressure, blood glucose levels, blood lipid levels, inflammatory and satiety serum markers and self-reported quality of life in overweight adults encouraged to reduce calories and exercise regularly, but on an unrestricted diet and without specific exercise instruction. Specifically, to demonstrate an improvement in hunger/satiety and a clinically meaningful improvement in other measures in a group of overweight adults after 3 months of daily consumption of the ISOThrive supplement.
- To demonstrate the safety of the ISOThrive supplement in terms of its impact on blood, liver and kidney function in overweight adults. Specifically, to demonstrate the lack of a negative impact on blood, liver and kidney function tests in a group of overweight adults after 3 months of daily consumption of the ISOThrive supplement.
- To determine the effects of the ISOThrive supplement on Gut health. Specifically, to demonstrate improvement in Gut health as measured by abdominal bloating, abdominal gas, and abdominal pain/discomfort at the end of 3 months of daily consumption of the ISOThrive supplement.
Study Type
Interventional
Enrollment (Actual)
103
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
Derby, Connecticut, United States, 06418
- Yale-Griffin Prevention Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- BMI of 25 and over and weight not > 350lb
- Age between 18 and 75
- Non-smokers
- Able to read and write in English
Exclusion Criteria:
- Pregnant and/or lactating women
- Evidence or history of substance or alcohol abuse (include if over 5years)
- History of major depression, bipolar disorder or schizophrenia, any type of obsessive-compulsive disorder
- Current history of migraine headaches (include if controlled with medication)
- Current use of any prescription or non-prescription weight loss products
- Tobacco use
- Active eating disorder including anorexia nervosa and bulimia
- Known sensitivity or allergy to any of the ingredients in the product
- Symptomatic coronary artery disease or congestive heart failure
- History of a stroke in the past year
- Symptomatic arrhythmia
- Uncontrolled hypertension (i.e. systolic pressure >180 mmHg and or diastolic > 110 mmHg)
- History of a seizure in the past 5 years
- Any cancer in the past 5 years other than non-melanoma skin cancer or in-situ cervical cancer
- Active or history of inflammatory bowel disease
- Current use of TNF-alpha inhibitor medications
- Current use of COX-2 inhibitor medications
- Current use of JAK inhibitor medications
- History of weight loss procedures including bariatric surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ISOThrive supplement 1
Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months.
Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
|
Consumption of ISOThrive supplements for 3 months
|
Active Comparator: ISOThrive supplement 2
Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months.
Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
|
Consumption of ISOThrive supplements for 3 months
|
Placebo Comparator: Placebo supplement
Participants assigned to the placebo supplement arm will be provided with daily servings of a supplement for 3 months.
Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
|
Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body Weight
Time Frame: Up to 12 weeks
|
Body weight will be measured at the beginning and at the end of the study using a calibrated digital scale.
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hunger/satiety
Time Frame: Up to 12 weeks
|
will be assessed at the beginning and at the end of the study using a Visual Analog Scale (VAS) that will ask participants a series of questions to be completed at 2 time points: mid-morning between breakfast and lunch, and late evening between dinner and bed time.
The VAS questions require participants to rate on a scale the strength of specific sensations they are feeling (i.e., hunger, thirst, amount of food they could eat "right now", nausea, and fullness) by placing a vertical mark on the scale in response to each question.
|
Up to 12 weeks
|
Satiety indicators
Time Frame: Up to 12 weeks
|
will be assessed at the beginning and end of the study with biological markers using Glucagon-like peptide-1 (GLP-1), PYY and ghrelin.
|
Up to 12 weeks
|
Dietary intake data
Time Frame: Up to 12 weeks
|
Dietary intake will be assessed at the beginning and at the end of the study.
Each participant will complete three 24-hour dietary recalls (two for weekdays, and one for a weekend day) using an online Automated Self-Administered 24-Hour Recall (ASA24) (available from the National Cancer Institute at http://riskfactor.cancer.gov/tools/instruments/asa24/).
This data will be used to provide a representational measure of intake of kilocalories and macronutrients (protein, fat, and carbohydrates).
|
Up to 12 weeks
|
Body mass index (BMI)
Time Frame: Up to 12 weeks
|
will be measured at the beginning and at the end of the study .
BMI will be calculated as weight (kg) divided by height in meters (m) squared.
Height will be measured by using a calibrated stadiometer.
|
Up to 12 weeks
|
Body composition
Time Frame: Up to 12 weeks
|
will be measured using bioelectrical impedance analysis, which uses the resistance of electrical flow through the body to estimate body fat.
The Tanita SC-240 Body Composition Analyzer will be used to measure body composition.
The SC-240 Body Composition Analyzer measures weight and calculates body fat percentage and total body water percentage in addition to BMI.
Measures will be taken at baseline, 6 weeks and at the end of the 3-month intervention period.
|
Up to 12 weeks
|
Leptin
Time Frame: Up to 12 weeks
|
Leptin levels will be used as a biomarker to monitor the amount of body fat.
Leptin level will be assessed at the beginning and at the end of the study .
Leptin is a hormone secreted exclusively by adipose cells in response to an increase in body fat mass, and is an important component in the regulation of long-term hunger and food intake.
Leptin serves as the brain's indicator of the body's total energy stores.
When leptin levels rise in the bloodstream they bind to receptors in arcuate nucleus (ARC).
Leptin suppress the release of neuropeptide Y (NPY), which in turn prevents the release of appetite enhancing hypocretin (orexins) from the lateral hypothalamus.
This decreases appetite and food intake, promoting weight loss.
It also stimulates the expression of cocaine- and amphetamine-regulated transcript (CART).
|
Up to 12 weeks
|
Waist circumference
Time Frame: Up to 12 weeks
|
will be measured at the beginning and end of the study using guidelines of the National Obesity Expert Panel Report.
|
Up to 12 weeks
|
Blood pressure
Time Frame: Up to 12 weeks
|
will be measured by using a Dinamap Monitor Pro 100 (GE Healthcare, Piscataway, NJ) after sitting for 5 minutes.
Both systolic and diastolic pressures will be calculated as the mean value of 2 readings 5 minutes apart for each participant at every time point of assessment.
Blood pressure will be assessed at baseline, 6 weeks, and at the end of 3 months
|
Up to 12 weeks
|
Homeostasis model assessment of insulin resistance (HOMA-IR)
Time Frame: 12 weeks
|
will be measured in a fasting state at baseline and 12 weeks.
Homeostasis model assessment of insulin resistance (HOMA-IR) values will be calculated from fasting serum glucose and serum insulin levels to gauge the degree of insulin resistance.
|
12 weeks
|
Blood Lipid levels
Time Frame: Up to 12 weeks
|
Total cholesterol (Tchol), triglycerides (TRIG), and high-density lipoprotein (HDL) will be obtained by direct measurements.
Very-low-density lipoprotein (VLDL) and low-density-lipoprotein (LDL) are obtained by calculation: VLDL = TRIG/5; and LDL = Tchol - (VLDL + HDL).
The HDL:Tchol ratio will be used to evaluate the impact of the supplement on lipid panel.
The lipid profile will be assessed at baseline and at the end of 3 months.
|
Up to 12 weeks
|
Abdominal symptoms
Time Frame: 12 weeks
|
We will assess abdominal bloating, abdominal gas, and abdominal pain/discomfort at 6 weeks and at the end of 3 months.
Abdominal symptoms will be assessed using a side effects survey.
|
12 weeks
|
Change in Quality of life
Time Frame: Up to 12 weeks
|
will be assessed using the SF-12 (http://www.sf-36.org/tools/sf12.shtml).
The SF-12v2 Health Survey uses 12 questions to assess 8 domains of health and well-being (general health, physical function, physical role, bodily pain, mental health, emotional role, vitality, and social function) within the past 4 weeks.
The SF-12v2 is a practical, reliable, and valid measure of physical and mental health and takes only 2 to 3 minutes to complete.
This tool will be administered at baseline and at the end of 3 months.
|
Up to 12 weeks
|
Liver function
Time Frame: Up to 12 weeks
|
will be assessed at baseline and at the end of 3 months via a comprehensive metabolic panel to explore the safety of the ISOThrive supplement.
Liver function will be evaluated based on levels of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, and bilirubin.
|
Up to 12 weeks
|
Kidney function
Time Frame: Up to 12 weeks
|
Kidney function will be evaluated using blood urea nitrogen and creatinine.
|
Up to 12 weeks
|
Urine
Time Frame: Up to 12 weeks
|
Urine samples will be collected from participants at baseline and at the end of 3 months.
Urinalysis will be used to detect substances or cellular material in the urine associated with different metabolic and kidney disorders.
|
Up to 12 weeks
|
Complete blood count
Time Frame: Up to 12 weeks
|
will be performed to assess the different components of blood.
|
Up to 12 weeks
|
Stool
Time Frame: Up to 12 weeks
|
The stool analysis will be done with samples taken for a subset of 40 subjects.
DNA extraction (i.e.
purification of DNA from sample), LH-PCR Fingerprinting (i.e to amplify a single copy or a few copies of a piece of DNA across several orders of magnitude, generating thousands to millions of copies of a particular DNA sequence), and Multitag Pyrosequencing (i.e.
determining the order of nucleotides in DNA based on the "sequencing by synthesis" principle) will be done with the collected stool at one week before the start of the intervention (i.e. one week before taking product), the day before the start of the intervention, and at the end of 3 months.
|
Up to 12 weeks
|
Inflammatory biomarkers
Time Frame: Up to 12 weeks
|
High sensitivity C-reactive protein, TNF, IL6, IL10 and Interferon gamma will be used to monitor inflammation in our study participants.
These biomarkers will be assessed at baseline and at the end of 3 months.
|
Up to 12 weeks
|
Physical activity
Time Frame: Up to 12 weeks
|
Physical activity will be assessed at baseline and at the end of 3 months.
PA will be assessed by the International Physical Activity Questionnaire (IPAQ).31
The IPAQ is a valid and reliable tool to assess physical activity in adults.
It is a more comprehensive tool containing information on weekly activities in household and yard-work activities, occupational activity, transport, leisure time physical activity and sedentary behavior.
|
Up to 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Valentine Y. Njike, MD,MPH, Yale-Griffin Prevention Research Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2015
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
April 22, 2015
First Submitted That Met QC Criteria
July 15, 2015
First Posted (Estimate)
July 17, 2015
Study Record Updates
Last Update Posted (Actual)
March 26, 2020
Last Update Submitted That Met QC Criteria
March 25, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on ISOThrive Supplement
-
ISOThrive Inc.CompletedConstipationUnited States
-
Texas Tech UniversityEHP LabsCompletedBody Weight Changes | Body Composition Changes | Anthropometric Changes | Metabolism Changes | Hemodynamic ChangesUnited States
-
Universidade Federal do AmazonasCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Hospital Universitario... and other collaboratorsCompletedOverweight | HypercholesterolemiaBrazil
-
Probi ABCompleted
-
Chair for Biomarkers of Chronic DiseasesKing AbdulAziz City for Science and TechnologyRecruitingObesity | Metabolic DiseaseSaudi Arabia
-
Wageningen UniversityCompletedInflammation | Glucose Tolerance | Lipid Homeostasis | Vascular FunctionNetherlands
-
Maastricht University Medical CenterNutricia ResearchRecruitingPulmonary Disease, Chronic ObstructiveNetherlands
-
NorthShore University HealthSystemAnn & Robert H Lurie Children's Hospital of Chicago; Northwestern University... and other collaboratorsCompletedPremature, Extremely Low Birth Weight Infants | Polyunsaturated Fatty Acid LevelsUnited States
-
Hospital Universitari Vall d'Hebron Research InstituteNot yet recruiting